TRDA
NASDAQ · Biotechnology
Entrada Therapeutics Inc
$12.03
+0.56 (+4.88%)
Open$11.82
Previous Close$11.47
Day High$12.15
Day Low$11.55
52W High$13.66
52W Low$4.93
Volume—
Avg Volume211.2K
Market Cap458.65M
P/E Ratio—
EPS$-3.47
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+50.0% upside
Current
$12.03
$12.03
Target
$18.04
$18.04
$12.20
$18.04 avg
$27.27
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 24.42M | 42.90M | 41.05M |
| Net Income | -138,094,592 | 8.98M | 10.98M |
| Profit Margin | -565.5% | 20.9% | 26.8% |
| EBITDA | -147,752,391 | 15.57M | 16.71M |
| Free Cash Flow | — | 11.03M | 8.57M |
| Rev Growth | — | +8.9% | +15.8% |
| Debt/Equity | — | 0.18 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |